AbbVie

AbbVie announced today that HUMIRA(R) (adalimumab) is now available for the treatment of paediatric patients aged six to 17 years with severe active Crohn's disease (CD) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications to such therapies. 

Abbott today announced it has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie will begin trading independently on the New York Stock Exchange today under the symbol "ABBV."